Rationale: Idiopathic pulmonary fibrosis (IPF) is a progressive inflammatory lung disease
without effective molecular markers of disease activity or treatment responses. Monocyte …

Purpose To characterize a chemokine receptor type 2 (CCR2)–binding peptide adapted for
use as a positron emission tomography (PET) radiotracer for noninvasive detection of lung …

Background Idiopathic pulmonary fibrosis (IPF) is a chronically progressive interstitial lung
disease of unknown etiology. Previously, we have demonstrated the selective upregulation …

Background Idiopathic pulmonary fibrosis (IPF) is a progressive disease for which two
antifibrotic drugs recently were approved. However, an unmet need exists to predict …

Idiopathic interstitial pneumonias (IIPs) are a collection of pulmonary fibrotic diseases of
unknown etiopathogenesis. CC chemokine receptor 7 (CCR7) is expressed in IIP biopsies …

Rationale: The chemokine receptors CXCR3 and CCR4 have recently been described as
playing a pivotal role in the mouse model of bleomycin-induced fibrosis. Objectives: To …

Idiopathic pulmonary fibrosis (IPF)/usual interstitial pneumonia (UIP) is the severest form of
idiopathic interstitial pneumonia for which therapeutic targets are needed. Surgical lung …

Pulmonary fibrosis is scarring of the lungs that can arise from radiation injury, drug toxicity,
environmental or genetic causes, and for unknown reasons [idiopathic pulmonary fibrosis …

Idiopathic pulmonary fibrosis (IPF), characterized by progressive worsening of dyspnea and
irreversible decline in lung function, is a chronic and progressive respiratory disease with a …

Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive pulmonary scarring disorder
in which individuals exhibit distinct clinical trajectories (1, 2). Currently, these trajectories are …